Senores Pharmaceuticals Ltd (SENORES) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544319 | NSE: SENORES | Pharmaceuticals & Drugs | Small Cap

Senores Pharmaceutic Share Price

777.40 -6.85 -0.87%
as on 05-Dec'25 16:59

Senores Pharmaceuticals Ltd (SENORES) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544319 | NSE: SENORES | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Senores Pharmaceutic

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Senores Pharmaceuticals stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
295.80
Market Cap:
3,611.8 Cr.
52-wk low:
440
52-wk high:
832

Is Senores Pharmaceuticals Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Senores Pharmaceutic: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Senores Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 2.9%5.5%2.6%2.2%-
Value Creation
Index
-0.8-0.6-0.8-0.8-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 13.512.43438.558
Sales YoY Gr.--8.6%174.7%13.3%-
Adj EPS 0.6-1.20.10.32.7
YoY Gr.--314%NA138.5%-
BVPS (₹) 38.539.755.1153.7155.1
Adj Net
Profit
0.5-1.20.41.412
Cash Flow from Ops. -24.1-43.4-62.8-20.4-
Debt/CF from Ops. -0.6-1.4-1.5-4.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANA41.7%13.3%
Adj EPS NANA-18.4%138.5%
BVPSNANA58.6%179%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
1.5-3.30.40.31.7
Op. Profit
Mgn %
8.5-14.4-0.2-19.1-8.3
Net Profit
Mgn %
3.7-9.71.13.721.1
Debt to
Equity
0.41.60.60.10
Working Cap
Days
01,7831,2622,0471,075
Cash Conv.
Cycle
0311157196934

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Senores Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 2.7 18.9
TTM Sales (₹ Cr.) 57.9 501
BVPS (₹.) 155.1 176.8
Reserves (₹ Cr.) 668 768
P/BV 5.06 4.44
PE 295.80 41.46
From the Market
52 Week Low / High (₹) 440.00 / 832.00
All Time Low / High (₹) 440.00 / 832.00
Market Cap (₹ Cr.) 3,612
Equity (₹ Cr.) 46.1
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Senores Pharmaceutic:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Senores Pharmaceutic - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Senores Pharmaceutic

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Sales14123439
Operating Expenses 12143446
Manufacturing Costs0035
Material Costs861918
Employee Cost 35918
Other Costs 1334
Operating Profit 1-2-0-7
Operating Profit Margin (%) 8.5%-14.4%-0.2%-19.1%
Other Income 17722
Interest 1237
Depreciation 1123
Exceptional Items 0000
Profit Before Tax 1225
Tax 0111
Profit After Tax 1114
PAT Margin (%) 5.0%9.7%2.4%9.6%
Adjusted EPS (₹)0.81.20.30.8
Dividend Payout Ratio (%)0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 3439168708
Share Capital 9103146
Reserves 2529138662
Minority Interest0000
Debt14322886
Long Term Debt12242076
Short Term Debt28810
Trade Payables641213
Others Liabilities 1367827
Total Liabilities 55112286834

Fixed Assets

Gross Block3102862
Accumulated Depreciation1247
Net Fixed Assets 282455
CWIP 3111834
Investments 12882104
Inventories3359
Trade Receivables8162226
Cash Equivalents flag 1010360
Others Assets 2665125247
Total Assets 55112286834

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -24-43-19-20
PBT 1225
Adjustment 1-2-3-10
Changes in Working Capital -25-43-18-14
Tax Paid -0-0-1-1
Cash Flow From Investing Activity -10-5-57-163
Capex -0-8-19-49
Net Investments 0000
Others -103-38-114
Cash Flow From Financing Activity 344787533
Net Proceeds from Shares 24337536
Net Proceeds from Borrowing 9131656
Interest Paid -1-2-3-6
Dividend Paid 0000
Others 13337-54
Net Cash Flow -0-210349

Finance Ratio

PARTICULARSMar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)2.023.30.780.84
ROCE (%)2.95.542.632.19
Asset Turnover Ratio0.250.150.170.07
PAT to CFO Conversion(x)-24-43-19-5
Working Capital Days
Receivable Days226355203226
Inventory Days80904162
Payable Days269325151253

Senores Pharmaceuticals Ltd Stock News

Senores Pharmaceuticals Ltd FAQs

The current trading price of Senores Pharmaceutic on 05-Dec-2025 16:59 is ₹777.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Senores Pharmaceutic stood at ₹3,611.8.
The latest P/E ratio of Senores Pharmaceutic as of 04-Dec-2025 is 295.8.
The latest P/B ratio of Senores Pharmaceutic as of 04-Dec-2025 is 5.06.
The 52-week high of Senores Pharmaceutic is ₹832.0 and the 52-week low is ₹440.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Senores Pharmaceutic is ₹57.86 ( Cr.) .

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as ‘Senores Pharmaceuticals Private Limited’ under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. The name of the Company was thereafter changed to ‘Senores Pharmaceuticals Limited’ upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.

Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing it as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, it strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets. 

It leverages its R&D capabilities to develop and manufacture a portfolio of differentiated complex pharmaceutical products. Its focus on quality and its ability to identify specialty and complex molecules has resulted in a pipeline of curated complex products spanning diverse dosage forms and therapeutic domains, demonstrated through its partnerships in the Regulated Markets of US, Canada and United Kingdom with foreign and Indian pharmaceutical companies.

Products of the company

Marketed Products

ANDA Products

  • Acetaminophen Butalbital and Acetaminophen Butalbital Caffeine
  • Chlorzoxazone
  • Diclofenac potassium
  • Ketorolac
  • Mexiletine Hydrochloride

Sourced Products

Awards, accreditations and recognitions

  • 2022: Its subsidiary, RPPL, obtained the ISO 9001:2015 certification in the ‘general’ section.
  • 2022: Its Subsidiary, RPPL, obtained the ISO 9001:2015 certification in the ‘B-lactum’ section.
  • 2023: Its Subsidiary, RPPL, received the WHO-GMP certificate from the FDA in the ‘manufacturer’ category.
  • 2023: Its Subsidiary, RPPL, received the GLP certificate from the FDA.
  • 2024: The Atlanta Facility of its Subsidiary, Havix, was audited and approved by the USFDA.

History and milestones

  • 2021: Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.
  • 2021: Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.
  • 2022: Started the domestic business with a launch of the critical care injectables.
  • 2023: Acquired majority stake in Havix., making it a Subsidiary of the company
  • 2023: Consolidated its presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making a subsidiary of the company.
  • 2024: Launched first CMO product in the US with Jubilant Cadista.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×